ENGIMMUNE THERAPEUTICS
Engimmune Therapeutics is a platform and product development company using cutting-edge technologies in the life sciences engineering highly potent and specific therapies based on T cell receptors (TCR) targeting solid tumors.
ENGIMMUNE THERAPEUTICS
Social Links:
Industry:
Biotechnology Therapeutics
Founded:
2021-08-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.engimmune.com
Total Employee:
1+
Status:
Active
Total Funding:
16 M CHF
Current Advisors List
Current Employees Featured
Founder
Investors List
Novo Holdings
Novo Holdings investment in Seed Round - Engimmune Therapeutics
Pureos Bioventures
Pureos Bioventures investment in Seed Round - Engimmune Therapeutics
BaseLaunch
BaseLaunch investment in Pre Seed Round - Engimmune Therapeutics
Official Site Inspections
http://www.engimmune.com Semrush global rank: 5.43 M Semrush visits lastest month: 1.56 K
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.186
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Engimmune Therapeutics"
Engimmune Therapeutics | T cell receptor therapies
Engimmune Therapeutics is a world-class developer of targeted, highly potent ‘off-the-shelf’ soluble T-cell receptor drugs (TCRs) to treat solid tumour cancers. Our cutting-edge proprietary platform technologies enable us to rapidly identify …See details»
Engimmune Therapeutics - Crunchbase Company …
Organization. Engimmune Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Engimmune Therapeutics is a platform and product development company …See details»
Success story Engimmune - BaseLaunch
Engimmune is a spinout from Prof. Sai Reddy’s research group at the Department of Biosystems Science and Engineering (D-BSSE) of the ETH Zürich in Basel. Built on foundational …See details»
Engimmune Therapeutics AG - SIP Basel Area
Engimmune Therapeutics AG. Engimmune is a Swiss biotech company applying innovative AI-guided protein engineering methods for targeted immunotherapy. engimmune.com. Read their …See details»
Engimmune Therapeutics - Overview, News & Similar companies
May 23, 2023 Engimmune Therapeutics, a Basel, Switzerland-based biotech company developing novel T-cell receptor (TCR)-based therapeutics, raised CHF 15.5M in Seed …See details»
Engimmune Therapeutics AG Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Engimmune Therapeutics AG of Allschwil, BASEL-LAND. Get the latest business insights from Dun & …See details»
Engimmune Therapeutics AG - Basel, Switzerland - bionity.com
About Engimmune Therapeutics. Engineering next-generation T cell receptor therapies. Read more about Engimmune Therapeutics Show less. Facts about Engimmune Therapeutics Facts …See details»
Engimmune Therapeutics AG - life-sciences-europe.com
Jan 1, 2021 Mouritsen, Søren (Engimmune Therapeutics 202205 CEO + Co-Founder) Person 2: Jakobsen, Bent (Accession Therapeutics 202109– CEO before Adaptimmune + Immunocore + …See details»
Engimmune Therapeutics - LinkedIn
Engimmune Therapeutics | 2,776 followers on LinkedIn. Engineering the next-generation of T cell receptor therapies against cancer | Engimmune is an immunotherapy company utilising cutting …See details»
Engimmune Therapeutics Drives Forward T-Cell Therapies Against …
Engimmune Therapeutics has received investments totaling 15.5 million Swiss francs for the development of novel T-cell receptor (TCR) therapeutics to combat cancer. The Basel-based …See details»
Engimmune Therapeutics - Contacts, Employees, Board Members, …
Organization. Engimmune Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 3. Number of …See details»
Engimmune Therapeutics - Products, Competitors, Financials, …
Clinical progress for three Biotechs. Dec 22, 2023. Background 22.12.2023 Oculis, EngImmune and Topadur are making progress in their clinical journey to advance treatments to save sight …See details»
News & Publications | Engimmune Therapeutics
Oct 11, 2022 Engimmune Therapeutics appoints Dr. Lars Nieba as Chief Executive Officer. April 19, 2023. Download PDF. Publications. High-throughput T cell receptor engineering by …See details»
Engimmune Therapeutics AG at the Swiss Biotech Day
Engimmune Therapeutics is a world-class developer of highly targeted, highly potent off-the-shelf soluble T-cell receptor drugs (TCRs) to treat solid tumour cancers.See details»
Engimmune Therapeutics - VentureRadar
Similar Companies: Dansk Biotek Unknown n/a DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, …See details»
Science | Engimmune Therapeutics
Engimmune’s proprietary AI-guided platforms accelerate the development of stable, soluble, multi-specific TCRs with extremely high affinity for their target antigens. We couple protein …See details»
Engimmune Therapeutics AG at the Swiss Biotech Day
Engimmune is a platform technology and product development company founded in August 2021 as a spin-off from ETH Zurich in Basel, Switzerland. We use an advanced protein engineering …See details»
Engimmune Therapeutics - Company Profile - Tracxn
Nov 3, 2024 Engimmune Therapeutics ranks 682nd among 2486 active competitors. 897 of its competitors are funded while 574 have exited. Overall, Engimmune Therapeutics and its …See details»
Pipeline | Engimmune Therapeutics
TCR-based therapies are an emerging class of drugs, which are broadly divided into TCR-redirected T cell therapies (TCR-T) and soluble TCR biologics (sTCRs) and leverage TCR …See details»
"T-cell receptor therapies against cancer are a highly ... - ETH Z
Oct 5, 2021 There is a big push in the field to bring down the costs of those T-cell therapies in order to be affordable for everyone and perhaps be incorporated in health care insurance …See details»